Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY) - Sorbonne Université
Journal Articles Open Forum Infectious Diseases Year : 2021

Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY)

Abstract

HIV-related inflammation is associated with poor outcomes. We describe inflammatory biomarkers in 17 participants in a pre-exposure prophylaxis trial who seroconverted with very early initiation of antiretroviral therapy. Inflammation peaked at the time of HIV infection and returned to baseline within 6-12 months. Starting antiretroviral therapy very early could help mitigate long-lasting HIV-related inflammation.
Fichier principal
Vignette du fichier
ofab085.pdf (369.29 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03230781 , version 1 (20-05-2021)

Identifiers

Cite

Sylvain Chawki, Isabelle Charreau, Audrey Gabassi, Diane Carette, Eric Cua, et al.. Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY). Open Forum Infectious Diseases, 2021, 8 (3), pp.ofab085. ⟨10.1093/ofid/ofab085⟩. ⟨hal-03230781⟩
30 View
25 Download

Altmetric

Share

More